SCHEMBL3235137

SCHEMBL3235137

CCOc1ccc2c(c1)C(C)(c1cc(C(=O)NCCN3CCN(C)CC3)ccc1Cl)C(=O)N2S(=O)(=O)c1ccc(C(=O)NC(C)(C)C)cc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AVPR1A P37288 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.39
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
CCR3 P51677 1/20 0.39
KMT2A Q03164 3/20 0.38
DDR1 Q08345 2/20 0.38
RAB9A P51151 1/20 0.38
LMNA P02545 2/20 0.37
HTT P42858 1/20 0.37
GLA P06280 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CCR2 P41597 3/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
DRD2 P14416 2/20 0.36
DRD4 P21917 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3239294 0.96 AVPR1A (0.56) AVPR1ASMN1; SMN2KDM4EALDH1A1DDR1
SCHEMBL3227252 0.96 AVPR1A (0.57) AVPR1ASMN1; SMN2GAAKDM4EALDH1A1
SCHEMBL3236940 0.94 AVPR1A (0.65) AVPR1ASMN1; SMN2GAAKDM4EALDH1A1
SCHEMBL3222842 0.91 AVPR1A (0.55) AVPR1ASMN1; SMN2KDM4EALDH1A1TSHR
SCHEMBL3231628 0.90 AVPR1A (0.53) AVPR1ASMN1; SMN2KDM4EKMT2ARAB9A
SCHEMBL3233606 0.90 AVPR1A (0.55) AVPR1ASMN1; SMN2KDM4EKMT2ARAB9A
SCHEMBL3238642 0.89 AVPR1A (0.57) AVPR1AALDH1A1KMT2A
SCHEMBL3232071 0.88 AVPR1A (0.51) AVPR1AALDH1A1TSHRKMT2ARAB9A
SCHEMBL3233637 0.88 AVPR1A (0.55) AVPR1ASMN1; SMN2KDM4ETSHRKMT2A
SCHEMBL3235348 0.87 AVPR1A (0.51) AVPR1AALDH1A1KMT2ARAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097374-B1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS SANOFI AVENTIS (FR) 2010-06-09 EP claimed
US-20100069384-A1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY SANOFI-AVENTIS (FR) 2010-03-18 US claimed
US-20100069384-A1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY SANOFI-AVENTIS (FR) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069384-A1 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AVPR2, AVPR1A, AVPR1B AVPR1A 2/4885SMN1; SMN2 4831/4885GAA 4723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.